Live case transmission designed to demonstrate ease-of-use and exceptional patient safety features of
CGuard™ Embolic Prevention System (EPS)
Tel Aviv, Israel — June 2, 2022 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will participate in the Leipzig Interventional Course (LINC) 2022, which is being held June 6-9 in Leipzig, Germany. The company will occupy Booth #36 during the conference.
“We are very pleased to again have a significant presence at this year’s LINC conference, including an opportunity to showcase the CGuard™ EPS stent system in a live case procedure that is designed to demonstrate its clinical utility, design superiority with sustainable protection, resulting in superior patient outcomes and safety,” said Marvin Slosman, chief executive officer of InspireMD. “This unique setting will give interventionalists an opportunity to see CGuard™ EPS in real-time and, we believe, add to the increasing number of clinicians who champion CGuard™ EPS with our unique MicroNet technology.
“We also look forward to talks by Drs. Savr Bugurov and Matteo Stefanini who will review their published evidence demonstrating the superiority of CGuard™ EPS relative to conventional first-generation open stent systems and to Professor Piotr Musialek’s new clinical evidence. The LINC conference continues to be an important platform for our engagement with the global clinical community and we are thrilled to be able to be back to a live format,” Mr. Slosman concluded.
Details of CGuard™ clinical presentations are as follows:
Date: Monday, June 6th
Time: 4:15pm – 4:20pm CEST
Room: 3 – Speaker’s Corner
Session: Latest results from clinical trials and innovations: Carotid/Venous/AV
Moderators: Manuela Kohnert, Daniela Branzan
Title: Randomized Controlled Trial of a First-Generation Carotid Stent vs. the MicroNet-Covered Stent: 12-Month Outcomes
Presenter: Savr Bugurov
Date: Wednesday, June 8th
Time: 11:00am – 11:45am CEST
Room: 1 – Main Arena
Session: Latest Techniques for Carotid Revascularization
Moderator: Dierk Scheinert
Panel: Piotr Musialek, Matteo Stefanini, Ralf Langhoff
11:00am CEST: CGuard Live case transmission from Heart Center, Leipzig, Germany
Operator: Andrej Schmidt
Title: MicroNet-Covered Stent in Stroke Prevention and Treatment: New Evidence
Presenter: Piotr Musialek
Title: Stent properties and vessel adaptability: could these factors influence procedural outcomes?
Presenter: Matteo Stefanini
LINC, the LEIPZIG INTERVENTIONAL COURSE is strongly committed to contribute to a systematic scientific evaluation and interdisciplinary discussion of new methods in the field of vascular medicine, allowing conclusions for daily interventional practice. LINC is an interdisciplinary live course, designed to provide a global platform, permitting the discussion of the “vascular patients” by integrating colleagues of different specialties from around the world who are performing endovascular interventions.
For more information, please visit: https://www.leipzig-interventional-course.com/
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
For more information, please visit www.inspiremd.com.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Chief Financial Officer
Chuck Padala, Managing Director